Logo

Lucence LiquidHallmark Expanded Assay

Jan 10, 2022

Lucence has launched an expanded version of its flagship LiquidHallmark liquid biopsy assay that includes both cell-free DNA and RNA profiling. The combined panel, available for US customers as a laboratory-developed test, includes cfRNA profiling of 27 actionable and emerging gene fusions and cfDNA profiling of mutations in 80 genes and fusions in 10 genes. The assay is powered by AmpliMark, the company’s proprietary amplicon-based sequencing technology, which uses molecular barcode and error-correction technology.

Breaking News
The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.